Oncology / NSCLC — Pharmacokinetics Simulators

3 interactive PK simulators available for oncology / nsclc drugs.

About Oncology / NSCLC Pharmacokinetics

Oncology pharmacokinetics encompasses the study of drug absorption, distribution, metabolism, and elimination of anti-cancer agents. Understanding PK properties is critical for optimizing dosing of chemotherapy, targeted therapies, immune checkpoint inhibitors, and antibody-drug conjugates to maximize efficacy while minimizing toxicity.

ALK/ROS1 Tyrosine Kinase Inhibitor

RMC

Oral• Population PK/PD

ALK-positive or ROS1-positive non-small cell lung cancer

Antibody-Drug Conjugate (ADC)

Patritumab Deruxtecan (HER3-DXd)

IV Infusion• Population PK (2-CMT ADC + 1-CMT DXd Payload)

EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload

EGFR Tyrosine Kinase Inhibitor

poppk

Oral• Population PK/Exposure-Response

EGFR-mutated non-small cell lung cancer

Disclaimer: These simulators are for educational and research purposes only. Pharmacokinetic models are based on published literature and may not reflect individual patient variability. Not intended for clinical decision-making. Always consult prescribing information and clinical guidelines.

← All AreasAll SimulatorsCompare Drugs →